Tag: file

Palo Alto, California, June 30, 2025 (GLOBE NEWSWIRE) --  NMP Acquisition Corp. (the “Company”) today announced the pricing of its initial public offering of 10,000,000 units at an offering price of $10.00 per unit, with each unit consisting of one Class A ordinary share and one right. Each right entitles the holder to receive one-fifth (1/5) of one Class A ordinary share upon consummation of the Company’s initial business combination. In connection with the offering, $10.00 per unit will be deposited into a trust account with Continental Stock Transfer & Trust Company acting as trustee. Up to $300,000 of interest earned on the funds held in the trust account, in the aggregate, may be released to us to fund our working capital requirements.  In addition, we may withdraw interest earned on the trust to pay our income and franchise taxes, if any. The units are expected to trade on the Nasdaq Global Market (“Nasdaq”) under the ticker symbol “NMPAU” beginning on July 1, 2025. Once the securities comprising the units begin separate trading, the Class A ordinary shares and rights are expected to trade on Nasdaq under the symbols “NMP” and “NMPAR,” respectively.

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor^® (rexlemestrocel-L) in the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation.

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) --

Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Guaranty Bancshares, Inc. (NYSE: GNTY) related to its sale to Glacier Bancorp, Inc. Upon completion of the proposed transaction, existing Guaranty shareholders will receive 1.0000 share of Glacier common stock for each share of Guaranty (subject to certain adjustments). Is it a fair deal?

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Turnstone Biologics Corp. (NASDAQ: TSBX) related to its sale to XOMA Royalty Corporation in which existing Turnstone shareholders will receive $0.34 in cash per share and one non-transferable contingent value right. Is it a fair deal?

THORNTON, Colo., June 30, 2025 (GLOBE NEWSWIRE) -- Ascent Solar Technologies, Inc. (NASDAQ: ASTI) (“Ascent” or the “Company”), the leading U.S. innovator in the design and manufacture of featherweight, flexible, and durable CIGS thin-film photovoltaic (PV) solutions, today announced the closing of its previously announced public offering of an aggregate of 1,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 1,000,000 shares of common stock (the “Warrants”), at a combined public offering price of $2.00 per share (or per pre-funded warrants in lieu thereof) and accompanying Warrant. The Warrants have an exercise price of $2.00 per share, are exercisable immediately upon issuance, and expire on the five-year anniversary of the initial issuance date.

Investors can contact the law firm at no cost to learn more about recovering their losses

BENSALEM, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for AISight® Dx*—its digital pathology image management system—for use in primary diagnosis in clinical settings. Building on the initial 510(k) clearance for AISight Dx(Novo) in 2022, this latest milestone underscores the platform’s continuous innovation and PathAI’s commitment to delivering enhanced capabilities as the product evolves.

Company Announcement No 55/2025